11 July 2025 - Astellas Korea will reapply for health insurance coverage for its new drug Vyloy (zolbetuximab), a targeted treatment for Claudin 18.2 gastric cancer.

Earlier this month, Astellas Korea submitted an application to the health insurance authorities for coverage of Vyloy. The reapplication comes about four months after the drug was rejected by the Health Insurance Review and Assessment Service's Cancer Disease Review Committee in February.

Read Korea Biomedical Review article